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Polyoxomolybdates (PMs) as discrete molybdenum-oxide cluster anions have been investigated in the course of study of their
medical applications. Here, we show the significant antitumour potency of the polyoxomolybdate [Me3NH]6[H2Mo
V
12O28(OH)12
(Mo
VIO3)4] 2H2O (PM-17), which is a photo-reduced compound of [NH3Pr
i]6[Mo7O24] 3H2O. The effect of PM-17 on the
growth of cancer cell lines and xenografts was assessed by a cell viability test and analysis of tumour expansion rate. Morphological
analysis was carried out by Hoechst staining, flow-cytometric analysis of Annexin V staining, terminal deoxynucleotidyl transferase-mediated
‘nick-end’ labelling staining, and electron-microscopic analysis. Activation of autophagy was detected by western blotting and
fluorescence-microscopic analysis of the localisation of GFP-LC3 in transfected tumour cells. PM-17 inhibited the growth of human
pancreatic cancer (AsPC-1) xenografts in a nude mice model, and induced morphological alterations in tumour cells.
Correspondingly, PM-17 repressed the proliferation of AsPC-1 cells and human gastric cancer cells (MKN45) depending on the
dose in vitro. We observed apoptotic patterns as the formation of apoptotic small bodies and translocation of phosphatidylserine by
Hoechst staining and flow-cytometric analysis following Annexin V staining, and in parallel, autophagic conformation by the
formulation of autophagosomes and localisation of GFP-LC3 by electron- and fluorescence-microscopic analysis.
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Pancreatic cancer is an aggressive form of cancer, and has one of
the poorest outcomes of all cancers (Jemal et al, 2005; Tani et al,
2006). Less than 10% of newly diagnosed pancreatic cancer
patients achieve 5-year survival (Fakih, 2006). Although the
clinical investigation of several antitumour agents has been
conducted with a principal focus on fluorouracil, no agent has
been found to suppress tumour growth. Also, there is no obvious
improvement in the results of treatment with multiple drug
therapy (Kelsen et al, 1991; Topham et al, 1991; Rougier et al, 1993;
Nose et al, 1999) or the biochemical modulation of fluorouracil
(Pazdur et al, 1992; Louvet et al, 1993; Weinerman and
MacCormick, 1994; Bernhard et al, 1995). Gemcitabine, a nucleoside
analogue, is efficacious in relieving the symptoms such as algia
or general state in the case of nonscaling down of tumours
(Casper et al, 1994). Furthermore, since the gemcitabine group has
a beneficial effect on survival rate compared with the fluorouracil
group, gemcitabine is the drug of choice for progressive pancreatic
cancer at present. However, in recent findings, there is a significant
toxic effect of gemcitabine combined with radiation in the
treatment of advanced pancreatic cancer (McGinn et al, 2001,
2002; Wolff et al, 2001; Crane et al, 2002). In addition, since
existing antipancreatic cancer drugs have no eradicative potency, it
is necessary to find medicines that have new mechanisms of
antitumour activity.
Dramatic improvement has been made in the treatment of
patients by modern chemotherapeutic protocols, which are based
on the dose-dependent antitumour activity of cisplatin (CDDP).
However, the excellent antitumour activity of CDDP is accom-
panied by strong toxic effects. From chemical analogy with CDDP,
antitumour active organometallic compounds such as titanocene
dichloride, copper (I), silver (I), and gold (I or III) tetrahedral
diphosphine complexes, and organosilicone compounds such as
trimethylsilylethylthioethylamine and its derivatives, have been
found (Fujita et al, 1990). In the course of examination of the
biological effects of polyoxometalates, inorganic polymers of metal
oxide, significant antitumour effects of polyoxomolybdates were
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sfound against conventional murine tumours (Fujita et al, 1992).
[NH3Pr
i]6[Mo7O24] 3H2O (PM-8) was found to exhibit potent
antitumour activity against MX-1 human breast cancer, Meth-A
sarcoma, and MM46 adenocarcinoma in vivo (Yamase et al, 1988).
Recent work from our laboratory showed that the efficacy of PM-8
has been recognised also for both AsPC-1 human pancreatic
cancer and MKN45 human gastric cancer, which results from
activation of the apoptotic pathway (Ogata et al, 2005; Mitsui et al,
2006; Yanagie et al, 2006). It has been proposed that PM-8 could be
preferentially taken into tumour cells and converted into an
approximately 10-fold more toxic species, produced through
biological reduction probably in the mitochondrial system. This
would inhibit ATP generation, and such a significant difference in
toxicity between PM-8 and its reduced species would lead to a
tumour-selective inhibition. This is based on the enhanced
metabolism in tumour cells, since the high molecular weight of
the reduced species (as a condensed species) would result in a
longer stay in the tumour cells (Yamase, 2005).
In this study, we show noticeable antitumour activity of PM-17
(¼[Me3NH]6[H2Mo
V
12O28(OH)12(Mo
VIO3)4] 2H2O), one of the
reduced species of PM-8, in the treatment of AsPC-1 cells and (or)
MKN45 cells in vitro and in vivo. Furthermore, we aimed to clarify
the mechanism of the anticancer effects of these compounds.
MATERIALS AND METHODS
PM-8 and PM-17
PM-8 was synthesised according to the published procedure
(Yamase and Ikawa, 1977). PM-17 was prepared as follows: an
aqueous solution (20ml) of PM-8 (0.3g, 0.2mmol) in a Pyrex tube
was irradiated for 4 days using a 500-W superhigh-pressure
mercury/xenon lamp.
iPrNH2 was added dropwise to the dark
brown-coloured photolyte to adjust the pH to 8.8, then added
[Me3NH]Cl (1g, 10.4mmol), and followed by cooling at 41C.
Reddish-brown rod crystals of the photo-reduced product were
precipitated after 1–2 weeks and isolated by filtration. Yield:
64.3mg, 25.9% based on Mo. Calcd: N 3.03, C 7.78, H 2.83, Mo
55.3%; found: N 3.42, C 8.16, H 2.56, Mo 53.8%. Manganometric
redox titration showed the presence of 11.6±0.1 Mo
V centres
in PM-17. Together with the X-ray crystallographic results
(Yamase and Ishikawa), the elemental analysis enabled us to
formulate PM-17 as given.
Animals and cell lines
Female nude mice (BALB/c, nu/nu) were purchased from Japan
SLC Inc. The experiments were performed with the permission of
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Figure 1 PM-17 inhibits tumour growth depending on the dose in vivo.( A) Variance of tumour volume. After 10 days implantation of 2 10
6 AsPC-1
cells in BALB/c nude mice, these mice were treated with 0.9% NaCl solution (’, n¼5), PM-17 (125mg per 100ml) (K, n¼5), and PM-17 (500mg per
100ml) (m, n¼5) intratumorally. The intratumoral injections were performed for 10 days with 2 days’ intermission on day 6. The tumour sizes were
measured using a micrometre caliper. Points, mean of tumour volume of five mice per group; bars, s.d. *Po0.05 compared with control. (B) Tumours of 41
days after implantation (left, saline control; right, PM-17 500mg per body treated). (C) Alteration of weight of tumour-bearing mice. Points, mean of
percentage of body weight per group.
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sthe Animal Ethics Committee of The University of Tokyo in
accordance with the Declaration of Helsinki. At the start of the
experiments, the mice were 7 weeks old and were kept under
controlled, specific pathogen-free conditions (temperature
23±21C, relative humidity 55±5% and 12h/12h light/dark cycle)
in isolation. An AsPC-1 human pancreatic cancer cell line and a
MKN45 human gastric cancer cell line were used in this study, and
were maintained in RPMI 1640 medium (GIBCO, Carlsbad, CA,
USA) supplemented with 10% FBS (CLONTECH Laboratories,
Mountain View, CA, USA), 100Uml
 1 of penicillin G, and
100Uml
 1 streptomycin in a 5% CO2 humidified atmosphere at
371C.
Tumour growth inhibition test
To estimate the antitumour effects of PM-17 on the proliferation of
AsPC-1 cells in vivo,2 10
6cells were transplanted into the back
of nude mice. After 10 days, intratumoral injections of PM-17
(125mg or 500mg dissolved in 100ml saline) were performed for 10
days with a 2-day intermission on day 6. The control mice were
treated with 100ml saline per day under the same conditions used
for the animals treated with PM-17. The tumour volume was
determined using the two principal perpendicular diameters as
V¼1/2 length (mm) (width (mm))
2.
Antibodies and chemicals
Antibodies were obtained from the following commercial sources:
anti-MAP LC3 (Santa Cruz Biotechnology Inc., Santa Cruz, CA,
USA); anti-b-actin antibody (SIGMA-Aldrich, Saint Louis, MO, USA).
Horseradish peroxidase-conjugated Streptavidin was purchased from
Amersham Biosciences (Buckinghamshire, UK). PM-17 was prepared
by the chemical synthesis group in our laboratory.
Cell viability assay
To determine the effect of PM-17 on tumour cells, we assessed cell
viability after treatment using the trypan blue dye exclusion assay
(Takeuchi et al, 2005). AsPC-1 and MKN45 in exponential growth
phase were harvested, seeded at 1.5 10
5cells per 6cm cell culture
dish (5ml), and incubated at 371Ci n5 %C O 2 in air overnight.
The cells were then incubated for 24h with or without PM-17 in
graduated concentrations from 0 to 230mgml
 1 (AsPC-1) and
from 0 to 60mgml
 1 (MKN45). After the cells were collected with a
scraper and stained with trypan blue, the viable cells were counted
using a haemocytometer. Considering the viability of untreated
cells (the control) as 100%, we calculated survival fractions from
the mean cell viability of the treated cells.
Quantification of apoptosis in situ
Analysis of DNA fragmentation of the lamellae of the tumour
by terminal deoxynucleotidyl transferase-mediated ‘nick-end’
labelling (TUNEL) was done using a POD labelling in situ cell death
detection kit (Roche, Basel, Switzerland). DNA fragmentation was
detected by enzyme reaction of labelled POD with DAB substrate
(Roche).
Detection of apoptotic small bodies
One million cells growing in 25cm
2 culture flasks were exposed to
PM-17 at concentrations of 175mgml
 1 (AsPC-1) and 40mgml
 1
(MKN45) for 24h. The cells were harvested and centrifuged at
200g for 10min before being washed and resuspended in
PBS containing 1mM Hoechst dye 33342 (SIGMA-Aldrich).
The apoptotic cells were visualised by fluorescence microscopy
(KEYENCE CORPORATION, Osaka, Japan).
Detection of DNA ladder
Cells growing in 10-cm diameter culture dishes were treated with
PM-17 at concentrations of 0 or 175mgml
 1 (AsPC-1) and 0 or
40mgml
 1 (MKN45) for 24h. Following centrifugation at 200g, the
harvested cells were lysed with DNA extraction buffer (10mM Tris-
HCl (pH 7.4), 10mM EDTA, 0.5% Triton X-100) and incubated at
41C for 10min. After centrifugation at 16000g for 5min, the cell
lysate was treated with 500mgml
 1 DNase-free RNase at 371C for
1h, followed by treatment with 500mgml
 1 proteinase K at 501C
for 30min. Electrophoresis in 1% agarose gels was then performed
and DNA ladders were visualised by UV illumination after staining
with ethidium bromide.
Quantification of disruption of cytoplasmic membrane
The translocation of phosphatidylserine from the inner part of the
plasma membrane to the outer layer was detected with Annexin-
V-FLUOS staining; the disruption of the cytoplasmic membrane
was analysed by the formulation of PI–DNA complexes by flow
cytometry with a FAC Sort FCM machine (Beckman Coulter,
Fullerton, CA, USA). The experiments were performed with
Annexin-V-FLUOS followed by staining with the Roche kit.
Measurement of caspase-3 activity
Activity of caspase-3 was measured by Caspase-Glot 3/7 Assay kit
(Promega Corporation, Madison, WI, USA). The assay provides a
proluminescent caspase-3/7 substrate, which contains the tetra-
peptide sequence DEVD. Luminescence is proportional to the
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Figure 2 The effect of PM-17 treatment on MKN45 cell and AsPC-1 cell
survival in vitro. MKN45 cells were treated with PM-17 at the
concentrations of 0–60mgml
 1 for 24h (A) and AsPC-1 cells were
treated at the concentrations of 0–230mgml
 1 for 24h (B). Points,
percentage of living cell in three independent experiments; bars, s.d.
Antitumour effect of polyoxomolybdates
A Ogata et al
401
British Journal of Cancer (2008) 98(2), 399–409 & 2008 Cancer Research UK
T
r
a
n
s
l
a
t
i
o
n
a
l
T
h
e
r
a
p
e
u
t
i
c
samount of caspase activity present. The experimental procedures
followed the manufacturer’s instructions. We measured the
intensity of luminescence with a Mithras LB 940 microplate reader
(Berthold Technologies, Bad Wildbad, Germany).
Western blot analysis
Two million cells were cultured in sterile 10cm dishes in 10% FCS/
RPMI 1640 culture medium overnight. Next day, the cells were
exposed to experimental medium with or without PM-17 (MKN45,
40mgml
 1; AsPC-1, 175mgml
 1) for 24, 48, or 72h. The cultured
cells were centrifuged at 200g for 5min at 41C and washed in
ice-cold PBS.
After centrifugation, the supernatant was removed and the cell
pellet was resuspended in 0.1ml lysis buffer (PBS, 1% Triton
X-100, 1% Nonidet P-40), and incubated at 41C for 30min. The
cells suspended in the buffer were centrifuged at 10000g for
10min at 41C, and then the supernatant (containing the total
protein fraction) was carefully transferred to a new tube. Each
sample, containing equal amounts of protein (80mg), was mixed
1:3 (vv
 1) with sample buffer (Wako Pure Chemical Industries
Ltd, Osaka, Japan) containing 20% 2-mercaptoethanol and boiled
for 5min. Samples containing identical quantities of protein were
subjected to SDS–PAGE (4–20% gradient gel) together with
biotinylated SDS–PAGE standards (Bio-Rad, Hercules, CA, USA).
Electrophoresis was performed for almost 1h at 40mA. After
electrophoresis, the separated proteins were electroblotted onto
PVDF membranes (Millipore Corporation, Bellerica, MA, USA) for
60min at 20V. The membranes were blocked for 1h with blocking
solution (Dainippon Sumitomo Pharma, Osaka, Japan) dissolved
in PBS-T (0.05% Tween 20 in PBS), then incubated with the
primary antibodies diluted with blocking solution at 41C. The
dilution rates of the antibodies were as follows: anti-MAP LC3
antibody 1:200 and anti-b-actin antibody 1:3000. The following
day, the membranes were rinsed three times for 10min each in
PBS-T at room temperature and incubated with HRP-labelled
secondary antibodies (1:3000) and HRP-conjugated Streptavidin
(1:3000) (GE Healthcare UK Ltd, Buckinghamshire, UK) diluted in
blocking solution for 1h at room temperature. The membranes
were then washed three times for 10min each in PBS-T and reacted
with ECL Plus Western Blotting Detection System (GE Healthcare
UK Ltd). Chemiluminescence was analysed by ChemiDoc XRS
(Bio-Rad).
Transmission electron microscopy
Cells were fixed in a mixture of 2.5% glutaraldehyde in 0.1 M
phosphate buffer, pH 7.4 for 2h at 41C, washed in 0.2 M sucrose/
0.1 M phosphate buffer, pH 7.4, for 2h, and postfixed with 1.5%
osmium tetroxide in 0.1 M phosphate buffer for 1h at room
temperature. The material was dehydrated in an ethanol gradient
(50, 70, 80, 90, and 100%) and propylene oxide, and embedded in
Epon 812. The blocks were cut with a microtome and stained with
4% uranyl acetate and Reynolds solution. Samples were photo-
graphed in a JEOL JEM-1200 EX electron microscope at 80kV.
Transfection and fluorescence microscopy
MKN45 cells and AsPC-1 cells were transfected using lipofecta-
mine 2000 reagent (Invitrogen, Carlsbad, CA, USA) and pGFP-LC3.
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Figure 3 Apoptosis detection in tumour cells treated with PM-17. (A) Hoechst 33342 staining. The tumour cells treated with PM-17 at the IC50
concentrations (AsPC-1, 175mgml
 1; MKN45, 40mgml
 1) for 24h were harvested and stained with Hoechst 33342. Arrows show apoptotic small bodies.
(B) DNA ladder formation of AsPC-1 and MKN45 after 24h treatment without or with IC50 of PM-17. DNA fragments derived from nontreated cells and
treated cells were electrophoresed in agarose gel with 100bp DNA ladder marker. (C) Flow-cytometric analysis by double-staining of Annexin-V-FLUOS
and PI on AsPC-1 and MKN45 after 24 and 48h treatment without or with IC50 of PM-17. (D) Activation of apoptosis signalling via caspase-3 activation in
MKN45 cells and AsPC-1 cells treated with PM-17. The variation of caspase-3 activity with time was analysed by measurement of chemiluminescence of a
proluminescent caspase-3/7 substrate. Columns, means of luminescence intensity response to activity of caspase-3 in three independent experiments; bars,
s.d. *Po0.05 compared with control, n¼3. (E) TUNEL staining of tumours injected with PM-8 (4mg per 100ml) or PM-17 (500mg per 100ml) or 100mlo f
0.9% NaCl solution as control once for all. The observations were made with a wide or narrow field of view as shown in panels.
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sOne day before transfection, 2 10
5cells were spread in 24 well
plates in 500ml growth medium. Then the transfection solution was
prepared as follows: in one tube, 0.8mg of DNA was diluted in 50ml
of serum-free medium and mixed gently, in the second tube, 2mlo f
lipofectamine 2000 reagent was diluted in 48ml of serum-free
medium and incubated at room temperature for 5min. After 5min
incubation, both solutions were carefully combined, mixed gently,
and incubated at room temperature for 20min. The cells were
washed, the transfection mixture (100ml each) was added, and
incubated at 371C, under 5% CO2 humidified atmosphere for 6h.
Afterwards, the transfection mixture was replaced with growth
medium. After 24h, transfected cells were treated with or without
PM-8 (MKN45, 900mgml
 1; AsPC-1, 1.65mgml
 1) or PM-17
(MKN45; 40mgml
 1, AsPC-1; 175mgml
 1) for 24h. The cells were
resuspended in PBS and transferred onto glass slides. The
fluorescence of GFP-labelled LC3 protein was observed by
fluorescence microscopy (Keyence Corporation).
Haematological examination and blood chemistry assay
BALB/c nude mice were transplanted with 2 10
6 AsPC-1 cells
into the back, and after 10 days, we carried out intratumoral
injections of PM-17 (500mg or 1mg per 100ml saline per day) for
10 days with a 2-day intermission on day 6. Control mice were
MKN45
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streated with 100ml of saline per day under the same conditions
used for animals treated with PM-17. Negative control mice
received neither tumour transplantation nor intratumoral injec-
tion. After 24h from the last intratumoral injection, mice were
anaesthetised and blood samples taken. Whole blood samples were
used for haematological tests. Blood sera were assessed for BUN,
creatinine, total bilirubin, total protein, AST, ALT, and ALP.
Statistical analysis
For the tumour cell inhibition assay in vivo, measurement of
caspase-3 activity assay, haematological examination, and blood
chemistry assay, statistical analysis was performed using t-test
between control and samples treated with PM-17. P-values less
than 0.05 indicate statistical significance.
RESULTS
PM-17 interferes with the growth of a solid tumour of
AsPC-1 in vivo
Timed measurements showed that PM-17 inhibited tumour growth
at rates of 33.5 and 68.3% at doses of 125mg and 500mg per body
per day (at 41 days after implantation of the tumour) compared
with the controls (Figure 1A and B). In addition, there was no loss
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sof body weight for mice injected with PM-17 in this experiment
(Figure 1C). These results show that PM-17 inhibits the prolifera-
tion of AsPC-1 human pancreatic tumours in a dose-dependent
manner in vivo.
Inhibition of tumour cell growth with PM-17 in vitro
We examined the cytotoxic effects of PM-17 on the growth of
AsPC-1 cells and MKN45 cells. These cells were suspended in
RPMI 1640 culture medium containing a range of concentrations
of PM-17. As shown in Figure 2, IC50 values of PM-17 against
AsPC-1 cells and MKN45 cells were 175 and 40mgml
 1,
respectively.
Apoptotic changes of tumour cells treated with PM-17
To investigate the mechanism of cell inhibition by PM-17,
morphological analysis by Hoechst staining was performed
to detect the formation of apoptotic small bodies, as shown in
Figure 3A. Sharp DNA laddering was observed after treatment with
PM-17 by agarose gel electrophoresis of cell DNA extracts, which
allowed us to confirm the induction of apoptosis by PM-17
(Figure 3B).
Flow-cytometric analysis using Annexin V and PI staining was
performed to determine the translocation of phosphatidylserine,
disruption of cytoplasmic membranes, and produce quantitative
results. Figure 3C shows that the ratio of apoptotic cells increased
with the duration of PM-17 treatment: approximately 19.9% after
24h and 77.8% after 48h in MKN45 cells, and 16.2% after 24h and
23.1% after 48h in AsPC-1 cells.
The activation of caspase-3 was obtained in MKN45 cells and
AsPC-1 cells treated with PM-17 as determined by Caspase-Glot
3/7 Assay. The substrate test used made it appear that caspase-3
was activated in both of the treated tumour cell lines (Figure 3D).
Moreover, TUNEL staining of thin sections of tumours after
single injections of PM-8 or PM-17 showed the induction of
cell degradation and DNA fragmentation (Figure 3E), and H&E
staining showed that tumour cells treated with PM compounds led
to hyalinisation by pathological observations. In the experiment,
nude mice were injected with 2 10
6 of AsPC-1 cells. After 10 days,
we gave single injections of PM-8 (4mg per 100ml saline) or PM-17
(500mg per 100ml saline) intratumorally. We then killed the mice
after 24h, eviscerated and fixed the tumours by freezing with
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sO.C.T. Compound (Sakura Finetechnical Co. Ltd, Tokyo, Japan).
Thin sections of tumours were stained with TUNEL stain. These
results showed that PM-8 and PM-17 induced apoptosis of tumour
cells in vivo.
Morphological analysis and detection of autophagic
features
Electron-microscopic analysis shows that mitochondria had
disrupted inner membranes in apoptotic MKN45 and AsPC-1
cells treated with PM-17 (Figure 4Aa, arrows). A number
of vesicles, figurative autophagosomes, were formed (Figure
4Ab, arrows) in MKN45 and AsPC-1 cells treated with PM-8 and
PM-17. Autophagic vacuoles contained cytosolic components and
organelles.
With a view to determine if an autophagic pathway or another
cell death pathway had been activated in the tumour cells or not,
we observed the localisation of LC3 after transient transfection (of
MKN45 cells and AsPC-1 cells) of a plasmid encoding GFP-LC3
24h after treatment with PM-8 or PM-17 (Figure 4B). LC3-II is a
truncated form of LC-3, and is necessary to combine with the
seclusion membrane for wrapping around cytoplasm components
fundamentally at random in the primary stage of autophagy
(Takeuchi et al, 2005). The GFP-LC3 was expressed and localised
on subcellular components, which were considered to be
autophagic vacuoles, upon treatment with PM-8 or PM-17 in
fluorescence microscopic observations. We also examined the
expression of LC3-II. Western blot analysis showed that the
expression of LC3-II protein increased in AsPC-1 cells treated with
PM-17 (Figure 4C). These results suggest that treatment with PM-
17 induces activation of two types of cell death pathway, not only
apoptosis but also autophagy.
DISCUSSION
Some polyoxomolybates such as PM-8, PM-17, PM-26, and PM-32
were found to exhibit antitumour activities against Co-4 human
colon tumour and Meth A sarcoma. In this research, we identified
PM-17 as an antitumour compound effective against human
pancreatic and gastric cancer cell lines, which induces apoptosis in
parallel with autophagy in tumour cells. In addition, PM-17 has
more potent antitumour activity than PM-8 in vivo (data not
shown). It is thought that PM-17 is an active state of PM-8 at inside
of the body or cells. PM-8 is reduced by electron transfer system in
mitochondria, and becomes PM-17, which is a more cytotoxic
a MKN45 AsPC-1
500 nm 500 nm
Control +PM-8 +PM-17
MKN45
AsPC-1
500 nm
500 nm
1  m
1  m
MKN45
GFP-LC3 GFP-LC3
AsPC-1
Control
+PM-8
+PM-17
AsPC-1 cells
Control PM-17
24 h
48 h
72 h
24 h
48 h
72 h
LC3- I (18 kDa)
LC3- II (16 kDa)
  -actin (43 kDa)
Figure 4 Morphological analysis and detection of autophagic feature. MKN45 cells were treated with PM-8 (900mgml
 1) or PM-17 (40mgml
 1), and
AsPC-1 cells were treated with PM-8 (1.65mgml
 1) or PM-17 (175mgml
 1). (A) Electron-microscopic analysis shows that mitochondria were disrupted.
Inner constitution ((a), arrows) and appearance of quantity of autophagic vacuoles ((b), arrows) in MKN45 and AsPC-1 treated with IC50 of PM-8 or PM-17
for 24h. (B) Subcellular localisation of GFP fusion LC3 protein in transfected MKN45 cells and AsPC-1 cells after treatment with or without IC50 of PM-8 or
PM-17 for 24h by fluorescent microscopy. (C) AsPC-1 cells treated with or without PM-17 (175mgml
 1) for 24, 48, and 72h. The cells were spun and
lysed, and each 80mg protein sample was loaded on SDS–PAGE gel and analysed by western blotting. Levels of LC3-I and -II expression were increased in
cells treated with PM-17. Experiments were performed twice.
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sagent (Yamase, 2005). Also we think that some of the antitumour
activity of PM-8 is derived from reduced species such as PM-17.
From recent reports, the role of autophagy in the maintenance of
cellular homoeostasis is becoming clearer. In normal cells,
autophagy plays a role in the exclusion of excessive or abnormal
proteins and organelles and in the recycling of cellular constituents
(Boya et al, 2005). In addition, autophagic cell death, through the
accumulation of autophagic vacuoles, affects degenerating neu-
rones in some pathological states (Fletcher et al, 2000; Larsen et al,
2002), participates in retinal degeneration (Guimaraes et al, 2003),
seals the fate of Salmonella-infected macrophages (Hernandez
et al, 2003), and mediates chemotherapy-induced tumour cell
death (Kanzawa et al, 2003, 2004; Opipari et al, 2004). However,
there are few examples of the role of autophagy in physiological
and pathological cell death because it is studied mainly based on
morphological grounds (Tsujimoto and Shimizu, 2005).
Historically, three types of cell death have been distinguished in
mammalian cells on morphological grounds; type 1 cell death
better known as apoptosis, type 2 is autophagic cell death, and type
3 is also better known as necrosis. The molecular signalling
systems of cell death have been elucidated progressively. In
parallel, research has been focused on the connection of signalling
between the different models of cell death. For example, in the
model of immortalised baby-mouse kidney epithelial cells, which
undergo cell death in response to hypoxia by knockdown of the
pro-apoptotic proteins (Bax and Bak), however, the overexpres-
sion of the antiapoptotic protein Bcl-2 causes a shift from
apoptosis to autophagic cell death (Golstein and Kroemer, 2007).
In addition, in another model, human breast cancer MCF-7 cells
exposed to camptothecin show rapidly induced apoptosis and
much slower autophagy. Bid, BH3-only pro-death Bcl-2 family
protein, knockout in MCF-7 cells results in suppression of
camptothecin-induced apoptosis and a shift of cell death towards
autophagy (Lamparska-Przybysz et al, 2005). These cases imply
that there is a cross network pathway of apoptosis and autophagy
in antitumoral cell death.
The results of our study show that PM-17 induces both
apoptosis and autophagy in human pancreatic cancer AsPC-1
cells. We examined apoptosis-inductive signalling in tumour cell
death, and neither activation of caspase-9 via the mitochondrial
system nor activation of caspase-8 via the cytoplasmic system,
known as representative apoptotic signalling systems, were
confirmed (data not shown). We also verified the activation of
caspase-3 and caspase-12 involved in ER stress signalling in
preliminary experiments. On the other hand, there was no increase
in PI3K(III) or Beclin-1, which were identified as regulatory factors
of autophagy. In addition, in our study, AsPC-1 cells were
pretreated with 3-MA (inhibitor of PI3K(III) in autophagy
signalling) at increasing concentrations from 0 to 1mM for
30min before treatment with IC50 of PM-17 for 1–24h, and
estimated cell viability using the MTT assay. In this model, the
inhibition of autophagy signalling by 3-MA had little effect on cell
death induced by PM-17. It is possible that PM-17 activates
autophagy through a different unknown route.
As another speculation, autophagy induced by PM-17 treatment
does not function as the confrontive death system, but could be a
reaction of the clearance system to the accumulation of dysfunc-
tional organelles such as mitochondria or proteins denatured by
chemotherapy. This mechanism could also be a rational way to
reutilise the components of dying cells as nutrients for remaining
cells. At present, we are proceeding to analyse the determination
factor of the magnitude of apoptosis and autophagy.
Furthermore, we carried out a toxicity test for PM-17 in mice by
haematological examination and serum chemistry (Table 1). In this
investigation, blood sera were assessed for BUN, creatinine, total
bilirubin, total protein, AST, ALT, and ALP. As a result, there was no
significant difference between the control and PM-17 groups. The
results showed that there was no impaired renal or hepatic function,
nor haematocytes in our administration model of PM-17.
In conclusion, PM-17 may be useful as a novel effective reagent
in treating pancreatic cancers, which generally have poor out-
comes. We plan to investigate the induction mechanism of tumour
cell death in detail, especially how PM-17 turns the cell death
programme on, and continue research for in vivo models of
antitumour therapy and the development of novel drug-delivery
systems using PM-17 (Yanagie et al, 1997, 2004, 2006).
Table 1 Haematological examination and blood chemistry
Group
WBC
( 10
3mm
 3)
RBC
( 10
5mm
 3)
HGB
(gdl
 1) HCT (%) MCV (lm
3) MCH (pg) MCHC (%)
PLT
( 10
3mm
 3)
Control 2.53±1.42 10.06±0.42 17.1±0.8 48.5±2.3 48.2±0.5 17.0±0.2 35.2±0.3 924±69
PM-17 500mg 4.08±1.23 10.18±0.32 17.1±0.7 48.9±1.8 48.0±0.5 16.8±0.2 35.0±0.3 750±148
PM-17 1000mg 4.51±2.54 9.76±0.16 16.7±0.3 46.4±0.7 47.6±0.7 17.1±0.2 36.0±0.7 1075±337
Negative
control
3.54±0.76 10.08±0.25 17.2±0.3 49.6±1.1 49.2±0.2 17.1±0.1 34.7±0.1 805±333
Differential leukocyte counts (%)
Group NEUT LYMPH MONO EOSN BASO LUC Reticulocyte (%)
Control 38.5±10.2 46.3±7.7 1.9±0.5 12.8±5.9 0.2±0.1 0.3±0.1 3.7±0.3
PM-17 500mg 26.3±8.4 60.7±11.6 2.1±0.5 10.2±5.8 0.2±0.1 0.5±0.3 3.5±0.4
PM-17 1000mg 30.5±6.0 56.3±17.3 2.0±0.4 10.6±12.0 0.1±0.1 0.4±0.2 3.5±0.6
Negative
control
20.6±1.8 68.2±7.8 1.6±0.1 9.2±6.4 0.3±0.1 0.4±0.2 4.0±0.5
Group Total protein
(gdl
 1)
AST (Ul
 1) ALT (Ul
 1)A L P
(Ul
 1)
Total bilirubin
(mgdl
 1)
BUN
(mgdl
 1)
Creatinine
(mgdl
 1)
Control 5.33±0.68 653±627 144±133 288±28 0.02±0.01 23.0±3.6 0.12±0.02
PM-17 500mg 4.94±0.21 236±162 117±117 263±21 0.02±0.02 19.4±2.6 0.10±0.02
PM-17 1000mg 4.97±0.23 301±93 96±66 250±33 0.01±0.02 23.9±1.0 0.13±0.02
Negative
control
4.76±0.08 337±114 271±156 357±40 0.00±0.00 29.6±0.4 0.13±0.02
Data indicate mean±s.d. per group. There is no significant difference between PM-17-treated groups and control.
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